1. Pretreatment (see Table on page 19). 
a. Complete physical examination noting in detail the exact size and 
location of any lesions that exist. 
b. Complete chemistry survey including electrolytes, liver function 
tests, calcium, magnesium, creatinine, BUN, CPK. 
c. CBC differential count, PT, PTT, platelet count 
d. Urine analysis and culture 
e. Hepatitis screen 
f. HIV titer 
g. Pregnancy test if woman between the ages of 16 and 50 
h. Chest x-ray 
i. Electrocardiogram 
j . Baseline x-rays and nuclear medicine scans to evaluate the status 
of disease. 
k. CT scan or MRI scan of brain 
l. 45 ml of clotted blood for serum storage and 45 ml of anti- 
coagulate blood for mononuclear cell cryopreservation. ^Selected patients may 
undergo pretreatment lymphocytapheresis . 
m. Biopsy of tumor, if possible with minimal morbidity 
2. During treatment . Patients will have a complete blood count and 
chemistry analysis panel at least every other day and a chest x-ray performed 
each week during treatment. 
During the infusion of the lymphocytes, patients will be .monitored 
closely in the Surgical Intensive Care Unit. Vital signs including blood 
pressure, pulse, and respirations will be measured every 15 minutes during the 
cell infusion and every 30 minutes for at least four hours or until the 
patient is stable. A pulse oximeter will be used for on-line measurement of 
oxygen saturation during and for the four hours after cell infusion as well. 
If the systolic blood pressure drops below 80 mm/Hg, or the oxygen saturation 
drops below 90% during the cell infusion, the cell infusion will be terminated 
immediately. 
[ 122 ] 
Recombinant DNA Research, Volume 15 
